Leigh Baldwin & CO. LLC Purchases Shares of 65,044 Pfizer Inc. (NYSE:PFE)

Leigh Baldwin & CO. LLC purchased a new position in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 65,044 shares of the biopharmaceutical company's stock, valued at approximately $1,726,000. Pfizer accounts for approximately 0.9% of Leigh Baldwin & CO. LLC's investment portfolio, making the stock its 13th largest position.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Tallon Kerry Patrick acquired a new stake in Pfizer during the fourth quarter worth approximately $509,000. Brighton Jones LLC grew its stake in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares during the period. CX Institutional grew its stake in Pfizer by 9.1% during the fourth quarter. CX Institutional now owns 50,390 shares of the biopharmaceutical company's stock worth $1,337,000 after purchasing an additional 4,183 shares during the period. Exchange Traded Concepts LLC grew its stake in Pfizer by 10.2% during the fourth quarter. Exchange Traded Concepts LLC now owns 76,250 shares of the biopharmaceutical company's stock worth $2,023,000 after purchasing an additional 7,072 shares during the period. Finally, Curated Wealth Partners LLC grew its stake in Pfizer by 25.6% during the fourth quarter. Curated Wealth Partners LLC now owns 45,337 shares of the biopharmaceutical company's stock worth $1,203,000 after purchasing an additional 9,236 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of PFE traded up $0.29 during mid-day trading on Tuesday, hitting $23.61. The stock had a trading volume of 36,119,931 shares, compared to its average volume of 41,080,360. The firm has a market cap of $134.23 billion, a P/E ratio of 16.74, a PEG ratio of 0.64 and a beta of 0.58. The business has a fifty day moving average price of $23.33 and a 200-day moving average price of $25.13. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.82 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.29%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.